Category - Markets

ANI Pharmaceuticals

Roth upgrades ANI Pharma to buy

Roth Capital Partners has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) to ”buy” from “neutral” but lowered its price target to $60 from $67. The stock closed at $43.21 on Friday. “We are upgrading shares of ANI...


HCW starts Conatus Pharma at buy

H.C. Wainwright has initiated coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a “buy” rating and $15 price target, saying that the company’s emricasan drug candidate has disease-modifying potential across the...


Can-Fite in $9-million registered direct offering

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with institutional investors to raise $9-million through the sale of 2,068,966 American Depository Shares (ADS) at a price of $4.35...

Cesca Therapeutics Logo

HCW upgrades Cesca Therapeutics to buy

H.C. Wainwright has upgraded Cesca Therapeutics (NASDAQ:KOOL) to “buy” from “neutral” with a new 12-month target price of $2 based on a discounted earnings/revenues analysis. The stock closed at 67 cents on Friday...